Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2710 | QazCovid-in® - COVID-19 inactivated vaccine Wiki | 1.00 |
drug370 | BCG-Denmark Wiki | 0.58 |
drug2985 | Saline Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.20 |
D018352 | Coronavirus Infections NIH | 0.16 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The COVID-19 pandemic challenges available hospital capacity. Strategies to protect health care workers (HCW) are desperately needed. Bacille Calmette- Guérin (BCG) has protective non-specific effects against other infections; a plausible immunological mechanism has been identified in terms of "trained innate immunity". The primary objective of the study is to evaluate whether BCG can reduce unplanned absenteeism due to illness among HCW during the COVID-19 pandemic. Secondary objectives are to reduce the number of HCW that are infected with COVID-19, reduce hospital admissions for HCW and to improve the capacity for clinical research. Design: Single-blind, parallel-group placebo-controlled multi-centre block randomized trial including a total of 1050 HCW. The study sites will be the Manhiça hospital in Mozambique, Central Hospital Dr. Agostinho Neto and Central Hospital Dr. Baptista de Sousa in Cape Verde and Hospital Nacional Simão Mendes and other hospitals in the capital Bissau in Guinea-Bissau. Population: HCW (nurses/physicians/others) ≥18 years. Intervention: Block randomization 1:1 to intradermal standard dose (0.1 ml) of BCG vaccine or placebo (saline). Endpoints: Primary: Days of unplanned absenteeism due to illness. Secondary: Days of absenteeism because of documented COVID-19; cumulative incidence of infectious disease hospitalizations. Follow-up: mobile phone interviews every second week, regarding symptoms, absenteeism and causes, COVID-19 testing (if done) and their results. Perspectives: If BCG can reduce HCW absenteeism it has global implications. The intervention can quickly be scaled up all over the world.
Description: Unplanned absenteeism is defined by being absent from work due to causes other than holidays, parental leave, and other planned leaves, family assistance (including mourning leave) and quarantine measures.
Measure: Days of unplanned absenteeism due to illness Time: 6 months after inclusionDescription: Unplanned absenteeism is defined by being absent from work due to causes other than holidays, parental leave, and other planned leaves, family assistance (including mourning leave) and quarantine measures.
Measure: Days of unplanned absenteeism due to documented COVID-19 Time: 6 months after inclusionDescription: Hospital admissions involves staying at a hospital for at least one night or more for medical reasons. It includes admissions to hospital wards and overnight stays in emergency departments.
Measure: Cumulative incidence of hospital admissions due to illness (minus accidents). Time: 6 months after inclusionDescription: Whether the participant died during follow-up
Measure: Death Time: 6 months after inclusionDescription: Refers to the number of nights of hospitalisation due to COVID-19
Measure: Hospitalisation for COVID-19 Time: 6 months after inclusionDescription: Refers to the number of nights of hospitalisation due to other reasons besides COVID-19
Measure: Hospitalisation besides COVID-19 Time: 6 months after inclusionDescription: Time, in days, from enrolment to first night of hospitalisation
Measure: Time to hospitalisation Time: 6 months after inclusionDescription: Time, in days, from enrolment to first day absent from work due to ill-health and disease
Measure: Time to absenteeism Time: 6 months after inclusionDescription: Refers to the number of days since enrolment to first day absent from work due to suspected COVID-19
Measure: Time to COVID-19 absenteeism Time: 6 months after inclusionDescription: Describes if the participant is positive for SARS-CoV2 or has had COVID-19
Measure: COVID-19 infection Time: 6 months after inclusionDescription: Time, in days, from enrolment to positive test for SARS-CoV2
Measure: Time to COVID-19 Time: 6 months after inclusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports